- Home
- ATNM vs FMST Comparison
ATNM vs FMST Comparison
Compare ATNM & FMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- FMST
- Stock Information
- Founded
- ATNM 2000
- FMST 2005
- Country
- ATNM United States
- FMST Canada
- Employees
- ATNM N/A
- FMST 2
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- FMST Other Metals and Minerals
- Sector
- ATNM Health Care
- FMST Basic Materials
- Exchange
- ATNM Nasdaq
- FMST Nasdaq
- Market Cap
- ATNM 51.5M
- FMST 39.6M
- IPO Year
- ATNM N/A
- FMST N/A
- Fundamental
- Price
- ATNM $1.47
- FMST $3.35
- Analyst Decision
- ATNM Strong Buy
- FMST
- Analyst Count
- ATNM 3
- FMST 0
- Target Price
- ATNM $4.67
- FMST N/A
- AVG Volume (30 Days)
- ATNM 518.4K
- FMST 911.7K
- Earning Date
- ATNM 08-04-2025
- FMST 01-01-0001
- Dividend Yield
- ATNM N/A
- FMST N/A
- EPS Growth
- ATNM N/A
- FMST N/A
- EPS
- ATNM N/A
- FMST N/A
- Revenue
- ATNM N/A
- FMST N/A
- Revenue This Year
- ATNM N/A
- FMST N/A
- Revenue Next Year
- ATNM N/A
- FMST N/A
- P/E Ratio
- ATNM N/A
- FMST N/A
- Revenue Growth
- ATNM N/A
- FMST N/A
- 52 Week Low
- ATNM $1.03
- FMST $0.55
- 52 Week High
- ATNM $8.64
- FMST $5.74
- Technical
- Relative Strength Index (RSI)
- ATNM 44.59
- FMST 49.42
- Support Level
- ATNM $1.41
- FMST $2.89
- Resistance Level
- ATNM $1.49
- FMST $3.95
- Average True Range (ATR)
- ATNM 0.12
- FMST 0.37
- MACD
- ATNM -0.02
- FMST -0.13
- Stochastic Oscillator
- ATNM 25.00
- FMST 34.91
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.